Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05198674 · ClinicalTrials.gov registry record · NA

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

A NA study of Hypertension and Cardiovascular Diseases, sponsored by Medtronic Vascular.

Active
Registry status
NA
Development phase
1,300
Enrollment target
20
Study locations

NCT05198674 is a NA study of Hypertension and Cardiovascular Diseases that is active but no longer recruiting, run by Medtronic Vascular. The registered enrollment target is 1,300 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05198674, a NA study of Hypertension and Cardiovascular Diseases, is active but no longer recruiting, sponsored by Medtronic Vascular.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
1,300 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.

Interventions

  • DEVICE Renal Denervation (Symplicity Spyral™)

Study Locations (20)

Florida

  • BayCare Health System - Clearwater
  • Clearwater Cardiovascular Consultants - Clearwater
  • Baptist Medical Center - Jacksonville
  • University of Miami Hosptial - Miami
  • AdventHealth Orlando - Orlando
  • Orlando Health Heart & Vascular Institute - Orlando
  • BayCare Medical Group - Safety Harbor
  • Tallahassee Memorial Healthcare, Inc - Tallahassee

Arizona

  • Banner Heart Hospital - Mesa
  • Abrazo Arizona Heart Hospital/Biltmore Cardiology - Phoenix
  • HonorHealth Research Institute - Scottsdale

California

  • Scripps Memorial Hospital - La Jolla
  • University of California, San Francisco - San Francisco
  • Stanford Hospital and Clinics - Stanford

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora
  • Colorado Heart and Vascular PC - Lakewood

Alabama

  • University of Alabama at Birmingham (UAB) Hospital - Birmingham

Arkansas

  • Arkansas Cardiology - Little Rock

Connecticut

  • Hartford Hospital - Hartford

District of Columbia

  • MedStar Washington Hospital Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 1,300 participants
Start Date 2021-10-20
Est. Completion 2029-11-30
Phase NA

Sponsor

Medtronic Vascular

26 total trials

What the Registry Record Tells You About NCT05198674

The ClinicalTrials.gov registry entry for NCT05198674 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (63% lower). The listed sponsor is Medtronic Vascular, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Renal Denervation (Symplicity Spyral™) is the first listed.

NCT05198674 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT05198674 about?

NCT05198674 is a clinical study titled "SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN". The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in th...

What is the current status of trial NCT05198674?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,300 participants. The study started on 2021-10-20. Estimated completion is 2029-11-30.

What conditions does trial NCT05198674 study?

This clinical trial studies the following conditions: Hypertension, Cardiovascular Diseases, Diabetes Mellitus, Chronic Kidney Diseases, Vascular Diseases.

What interventions are being tested in trial NCT05198674?

The interventions under investigation include: Renal Denervation (Symplicity Spyral™) (DEVICE).

Who is sponsoring clinical trial NCT05198674?

This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05198674 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.